全文获取类型
收费全文 | 3301篇 |
免费 | 247篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 30篇 |
儿科学 | 136篇 |
妇产科学 | 26篇 |
基础医学 | 483篇 |
口腔科学 | 46篇 |
临床医学 | 353篇 |
内科学 | 685篇 |
皮肤病学 | 38篇 |
神经病学 | 168篇 |
特种医学 | 422篇 |
外科学 | 491篇 |
综合类 | 61篇 |
一般理论 | 1篇 |
预防医学 | 178篇 |
眼科学 | 24篇 |
药学 | 147篇 |
肿瘤学 | 275篇 |
出版年
2021年 | 45篇 |
2019年 | 30篇 |
2018年 | 46篇 |
2017年 | 29篇 |
2016年 | 35篇 |
2015年 | 40篇 |
2014年 | 62篇 |
2013年 | 82篇 |
2012年 | 104篇 |
2011年 | 122篇 |
2010年 | 94篇 |
2009年 | 84篇 |
2008年 | 99篇 |
2007年 | 121篇 |
2006年 | 122篇 |
2005年 | 115篇 |
2004年 | 106篇 |
2003年 | 100篇 |
2002年 | 76篇 |
2001年 | 95篇 |
2000年 | 72篇 |
1999年 | 81篇 |
1998年 | 124篇 |
1997年 | 92篇 |
1996年 | 101篇 |
1995年 | 66篇 |
1994年 | 68篇 |
1993年 | 80篇 |
1992年 | 56篇 |
1991年 | 60篇 |
1990年 | 60篇 |
1989年 | 89篇 |
1988年 | 64篇 |
1987年 | 86篇 |
1986年 | 55篇 |
1985年 | 72篇 |
1984年 | 56篇 |
1983年 | 48篇 |
1982年 | 45篇 |
1981年 | 40篇 |
1980年 | 46篇 |
1979年 | 51篇 |
1978年 | 41篇 |
1977年 | 39篇 |
1976年 | 45篇 |
1975年 | 32篇 |
1974年 | 30篇 |
1973年 | 30篇 |
1972年 | 27篇 |
1970年 | 29篇 |
排序方式: 共有3564条查询结果,搜索用时 15 毫秒
61.
Gonzales AJ; Christensen JG; Preston RJ; Goldsworthy TL; Tlsty TD; Fox TR 《Carcinogenesis》1998,19(7):1173-1183
62.
Guo RJ; Wang Y; Kaneko E; Wang DY; Arai H; Hanai H; Takenoshita S; Hagiwara K; Harris CC; Sugimura H 《Carcinogenesis》1998,19(9):1539-1544
Mutations in the transforming growth factor beta type II receptor
(TGFbetaRII) gene have been detected in several human cancer types
exhibiting microsatellite instability. Using intron primers previously
reported for examination of the entire coding region of the TGFbetaRII
gene, 29 sporadic gastric cancers were screened with non-radioactive single
strand conformation polymorphism and subsequent DNA sequencing analysis.
Mutations of the TGFbetaRII gene were detected in three out of 29 tumors
(10%). Two cases showed deletions in a polyadenine tract in both alleles
and was positively associated with replication error. One case had an
insertion of GA dinucleotide sequence in one allele. Mutations of the
TGFbetaRII gene were restricted to exon 3 and other coding regions were not
affected. Loss of heterozygosity was detected by analyzing a polymorphic
site in intron 2. Three out of nine (33%) informative cases, which were all
of intestinal type and advanced cases, showed loss of heterozygosity but
neither TGFbetaRII mutation nor replication error was found in these cases.
Immunoreactivity of TGFbetaRII in tumor tissues was reduced to a different
extent in the gastric cancer with genetically abnormal transforming growth
factor. Although the numbers studied are small, homozygous (A)10 deletion
or loss of heterozygosity of TGFbetaRII is involved in tumorigenesis and
progression of at least some part of sporadic gastric cancer.
相似文献
63.
64.
Tumour cell growth may be accelerated by protein kinase C (PKC) agonists
such as phorbol esters and receptor tyrosine kinases, but receptor tyrosine
kinases are in turn desensitized to growth factors by PKC agonists. To
clarify this apparent PKC bifunctionality, we have used phosphoantibodies
to determine the relationship between PKC- dependent phosphorylation events
affecting the ErbB2 oncoprotein in G8/DHFR 3T3 cells. Neither the kinetics
nor the extent of phorbol- induced juxtamembrane domain (Thr686)
phosphorylation vary directly with C-terminal (Tyr1222) dephosphorylation,
with Tyr1222 continuing to be dephosphorylated long after Thr686
phosphorylation has also declined. Platelet-derived growth factor (PDGF)
mimics the short-term effects of phorbol on Thr686 and Tyr1222
phosphorylation, and confocal microscopy reveals that both of these PKC
agonists induce rapid internalization of PKC-modified ErbB2. Phorbol causes
sustained cytoplasmic accumulation of PKC-phosphorylated receptors,
however, whereas PDGF triggers the appearance of this ErbB2 subset only
briefly. Metabolic labelling and co-precipitation studies fail to implicate
heterologous molecules in either the tyrosine dephosphorylation or
internalization of PKC-modified ErbB2. Taken in the context of earlier
juxtamembrane domain mutagenesis studies, these findings indicate that
phorbol-activated PKC may desensitize growth factor receptors to
extracellular ligands solely by triggering sustained receptor
internalization. We submit that PKC-dependent juxtamembrane domain
phosphorylation represents a physiological mechanism for shortening the
duration and enhancing the specificity of growth factor signalling by
promoting internalization of liganded and unliganded receptors,
respectively.
相似文献
65.
66.
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. 总被引:4,自引:0,他引:4
Michael Atkins Meredith Regan David McDermott James Mier Eric Stanbridge Amanda Youmans Philip Febbo Melissa Upton Mirna Lechpammer Sabina Signoretti 《Clinical cancer research》2005,11(10):3714-3721
PURPOSE: Renal cancer response to interleukin 2 (IL-2) therapy and patient survival has been correlated with tumor histology and carbonic anhydrase IX (CAIX) expression. In an effort to confirm and expand these observations, we examined CAIX expression in pathology specimens from renal cancer patients who had previously received IL-2 therapy. EXPERIMENTAL DESIGN: Paraffin-embedded tissue sections of renal cancer were immunostained with the MN-75 monoclonal antibody to CAIX and expression levels were correlated with histologic findings and clinical outcome. RESULTS: Tissue specimens were obtained from 66 patients; 27 of whom (41%) had responded to IL-2-based therapy. Fifty-eight specimens were assessed as clear cell, with 56, 33, and 4 having alveolar, granular, and papillary features, respectively. Twenty-four (36%), 31 (47%), and 11 (17%) were classified into good, intermediate, and poor prognosis groups according to the Upton pathology model. Forty-one specimens (62%) had high CAIX expression. Twenty-one of 27 (78%) responding patients had high CAIX expressing tumors compared with 20 of 39 (51%) nonresponders (odds ratio, 3.3; P = 0.04). Median survival was prolonged (P = 0.04) and survival >5 years was only seen in high CAIX expressers. In patients with intermediate pathologic prognosis, all nine responders had high CAIX expression versus 11 of 22 nonresponders. A resultant group with good pathologic prognosis alone or with intermediate pathologic prognosis and high CAIX contained 26 of 27 (96%) responders compared with 18 of 39 (46%) nonresponders (odds ratio, 30; P < 0.01) and exhibited longer median survival (P < 0.01). CONCLUSIONS: CAIX expression seems to be an important predictor of outcome in renal cell carcinoma patients receiving IL-2-based therapy and may enhance prognostic information obtained from pathology specimens. 相似文献
67.
69.
70.